sofidexFor patientsAre you a clinician? Clinical site
Ask Sofi
Listen
Patient SupportEmergencies & Reporting
Log inSign up

Meds & supplements  ›  Futibatinib

Medicine · Kinase Inhibitor

Futibatinib

LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other…

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • This indication is approved under accelerated approval based on overall response rate and duration of response.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
  • LYTGOBI is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

What it is used for

LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Side effects, and when to stop

The following adverse reactions are discussed elsewhere in the labeling:

  • Ocular Toxicity
  • Hyperphosphatemia and Soft Tissue Mineralization

Who should not take it

None.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Futibatinib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/futibatinib

APA 7th

sofidex. (2026, August 2). Futibatinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/futibatinib

AMA 11th

Futibatinib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/futibatinib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.